AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28431766 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 717
Study 28431766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 717
Study 25403846 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate treatment for 3 years
Number of subjects: 0
Study 25403846 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term clinical study of ibandronate for 6 months
Number of subjects: 0
Study 24283768 — intervention group
Group type: EXPERIMENTAL
Intervention: ARVT+Jobelyn
Number of subjects: 51
Study 24283768 — intervention group
Group type: COMPARATOR
Intervention: ARVT
Number of subjects: 51
Study 20925684 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert-led (EX) strategy
Number of subjects: 92
Study 20925684 — intervention group
Group type: EXPERIMENTAL
Intervention: Train-the-trainer (TT) strategy
Number of subjects: 92
Study 20925684 — intervention group
Group type: COMPARATOR
Intervention: Self-study (SS) approach
Number of subjects: 92
Study 19459079 — intervention group
Group type: EXPERIMENTAL
Intervention: Superoxidized solution (SOS)
Number of subjects: 89
Study 19459079 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide (BP)
Number of subjects: 89
Study 19459079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 17299118 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise intervention (3-month duration, daily energy deficit of -45.7 +/- 12.4%)
Number of subjects: 12
Study 17299118 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exercising)
Number of subjects: 12
Study 15223200 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial Letter Fluency (ILF) task
Number of subjects: 20
Study 15223200 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic Category Fluency (SCF) task
Number of subjects: 20
Study 15223200 — intervention group
Group type: COMPARATOR
Intervention: Comparison with children with other psychopathology (N = 118)
Number of subjects: 20
Study 15223200 — intervention group
Group type: COMPARATOR
Intervention: Comparison with healthy controls (N = 130)
Number of subjects: 20
Study 12851990 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 0
Study 12851990 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0
Study 12851990 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab
Number of subjects: 0
Study 12851990 — intervention group
Group type: EXPERIMENTAL
Intervention: Alefacept
Number of subjects: 0
Study 9808499 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (GCV) 1000 mg every 8 hr for CrCl >50 ml/min
Number of subjects: 23
Study 9808499 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (GCV) 1000 mg every 24 hr for CrCl of 25-50 ml/min
Number of subjects: 23
Study 9808499 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (GCV) 500 mg every day for CrCl of 10-24 ml/min
Number of subjects: 23
Study 9808499 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (GCV) 500 mg every other day after dialysis for CrCl <10 ml/min
Number of subjects: 23
Study 9808499 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute bioavailability of oral GCV
Number of subjects: 23
Study 9808499 — intervention group
Group type: EXPERIMENTAL
Intervention: GCV concentrations before dialysis
Number of subjects: 23
Study 9808499 — intervention group
Group type: EXPERIMENTAL
Intervention: GCV concentrations after dialysis
Number of subjects: 23
Study 8694983 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic toothbrush (Sonicare)
Number of subjects: 116
Study 8694983 — intervention group
Group type: COMPARATOR
Intervention: Oscillating/rotating electric toothbrush (Braun Oral‐B Plaque Remover)
Number of subjects: 116
Study 2502905 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast neutron radiotherapy
Number of subjects: 0
Study 2502905 — intervention group
Group type: COMPARATOR
Intervention: Conventional megavoltage external beam irradiation
Number of subjects: 0
Study 189655 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐ and post‐operative radiotherapy
Number of subjects: 398
Study 189655 — intervention group
Group type: COMPARATOR
Intervention: Post‐operative radiotherapy alone
Number of subjects: 398
Study 189655 — intervention group
Group type: EXPERIMENTAL
Intervention: Single course of actinomycin D
Number of subjects: 398
Study 189655 — intervention group
Group type: COMPARATOR
Intervention: Multiple courses of actinomycin D
Number of subjects: 398
Study 189655 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with vincristine and actinomycin D for 6 months
Number of subjects: 398
Study 189655 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy with vincristine and actinomycin D for 15 months
Number of subjects: 398
Study 30926675 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant immunotherapy
Number of subjects: 0
Study 27860208 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methylnaltrexone 300 mg/day
Number of subjects: 803
Study 27860208 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methylnaltrexone 450 mg/day
Number of subjects: 803
Study 27860208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 803
Study 26088815 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegAsp (0.5 U/kg)
Number of subjects: 28
Study 26088815 — intervention group
Group type: COMPARATOR
Intervention: Biphasic insulin aspart 30 (control)
Number of subjects: 28
Study 23681505 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 318
Study 23681505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study 21211644 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide vaccine (3 nmol)
Number of subjects: 0
Study 21211644 — intervention group
Group type: COMPARATOR
Intervention: Cat allergen extract
Number of subjects: 0
Study 21211644 — intervention group
Group type: COMPARATOR
Intervention: Peptides
Number of subjects: 0
Study 19411814 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g of soy protein containing 160 mg of total isoflavones
Number of subjects: 93
Study 19411814 — intervention group
Group type: COMPARATOR
Intervention: Taste-matched placebo (20 g whole milk protein)
Number of subjects: 93
Study 17192117 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 802
Study 17192117 — intervention group
Group type: COMPARATOR
Intervention: Rosiglitazone
Number of subjects: 802
Study 15493856 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous gastric feeding
Number of subjects: 45
Study 15493856 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent gastric feeding
Number of subjects: 45
Study 11336582 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole, albendazole, and pyrantel pamoate
Number of subjects: 1000000000
Study 11336582 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive chemotherapy
Number of subjects: 1000000000
Study 9920356 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol supplementation (50 mg/day)
Number of subjects: 409
Study 9920356 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 409
Study 9920356 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol and ASA combined
Number of subjects: 409
Study 9920356 — intervention group
Group type: COMPARATOR
Intervention: No treatment (neither alpha-tocopherol nor ASA)
Number of subjects: 409
Study 9920356 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol supplementation
Number of subjects: 409
Study 8048523 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid inflation (170 ml/s)
Number of subjects: 19
Study 8048523 — intervention group
Group type: COMPARATOR
Intervention: Slow inflation (0.7 ml/s)
Number of subjects: 19
Study 3055321 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 64
Study 3055321 — intervention group
Group type: COMPARATOR
Intervention: Control (no TENS)
Number of subjects: 64
Study 29088019 — intervention group
Group type: COMPARATOR
Intervention: CE 0.625 mg alone
Number of subjects: 408
Study 29088019 — intervention group
Group type: EXPERIMENTAL
Intervention: CE 0.625 mg/BZA 5 mg
Number of subjects: 408
Study 29088019 — intervention group
Group type: EXPERIMENTAL
Intervention: CE 0.625 mg/BZA 10 mg
Number of subjects: 408
Study 29088019 — intervention group
Group type: EXPERIMENTAL
Intervention: CE 0.625 mg/BZA 20 mg
Number of subjects: 408
Study 29088019 — intervention group
Group type: EXPERIMENTAL
Intervention: CE 0.3 mg/BZA 20 mg
Number of subjects: 408
Study 29088019 — intervention group
Group type: EXPERIMENTAL
Intervention: CE 0.625 mg
Number of subjects: 408
Study 29088019 — intervention group
Group type: EXPERIMENTAL
Intervention: CE 0.3 mg with BZA 10 or 20 mg
Number of subjects: 408
Study 27627716 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact PCL-retaining TKA
Number of subjects: 78
Study 27627716 — intervention group
Group type: COMPARATOR
Intervention: Partial PCL-retaining TKA
Number of subjects: 78
Study 26347109 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (200 mg/m²), carboplatin (AUC 6), bevacizumab (15 mg/kg) with nitroglycerin patches (15 mg, day -2 to +2)
Number of subjects: 223
Study 26347109 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (200 mg/m²), carboplatin (AUC 6), bevacizumab (15 mg/kg) without nitroglycerin patches
Number of subjects: 223
Study 23734613 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized visuospatial memory training intervention
Number of subjects: 21
Study 23734613 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 21
Study 20810094 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflated tourniquet
Number of subjects: 245
Study 20810094 — intervention group
Group type: COMPARATOR
Intervention: Deflated tourniquet
Number of subjects: 245
Study 20810094 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 245
Study 19037034 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Abdominal Hysterectomy (TAH)
Number of subjects: 279
Study 19037034 — intervention group
Group type: COMPARATOR
Intervention: Subtotal Abdominal Hysterectomy (sub-TAH)
Number of subjects: 279
Study 19037034 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TAH and sub-TAH
Number of subjects: 279
Study 16166782 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg prednisolone once daily in the evening
Number of subjects: 10
Study 16166782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 14753640 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrinsic Atrioventricular Conduction (IAVC)
Number of subjects: 14
Study 14753640 — intervention group
Group type: COMPARATOR
Intervention: Permanent Ventricular Stimulation (PVS)
Number of subjects: 14
Study 10473307 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 31
Study 10473307 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal exposure
Number of subjects: 31
Study 10473307 — intervention group
Group type: COMPARATOR
Intervention: High EE relatives
Number of subjects: 31
Study 10473307 — intervention group
Group type: COMPARATOR
Intervention: Low EE relatives
Number of subjects: 31
Study 7491344 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A for 6 months
Number of subjects: 43
Study 7491344 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Number of subjects: 43
Study 7491344 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 43
Study 2016615 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole 2.5 mg/kg on 2 consecutive days weekly for 3 years
Number of subjects: 543
Study 2016615 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG for 3 years
Number of subjects: 543
Study 2016615 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG alternating with levamisole for 3 years
Number of subjects: 543
Study 2016615 — intervention group
Group type: COMPARATOR
Intervention: Control group (no further treatment)
Number of subjects: 543
Study 7259869 — intervention group
Group type: EXPERIMENTAL
Intervention: Korinfar 30 mg
Number of subjects: 11
Study 7259869 — intervention group
Group type: EXPERIMENTAL
Intervention: Korinfar 50 mg
Number of subjects: 11
Study 7259869 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoptin 120 mg
Number of subjects: 11
Study 7259869 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoptin 200 mg
Number of subjects: 11
Study 7259869 — intervention group
Group type: EXPERIMENTAL
Intervention: Korinfar
Number of subjects: 11
Study 7259869 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoptin
Number of subjects: 11
Study 7259869 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists (Korinfar and Isoptin)
Number of subjects: 11
Study 30597042 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor (dapagliflozin: ≤10 mg/day)
Number of subjects: 30
Study 30597042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 28316261 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced strength training with one session per week (RST1)
Number of subjects: 33
Study 28316261 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced strength training with two sessions per week (RST2)
Number of subjects: 33
Study 28316261 — intervention group
Group type: COMPARATOR
Intervention: Ceased training (CT)
Number of subjects: 33
Study 25716189 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive working memory training
Number of subjects: 130
Study 25716189 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized working memory training
Number of subjects: 130
Study 25716189 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected change in training task difficulty
Number of subjects: 130
Study 25716189 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 130
Study 24568978 — intervention group
Group type: EXPERIMENTAL
Intervention: Office-based nasolacrimal duct probing using topical anesthesia
Number of subjects: 304
Study 24568978 — intervention group
Group type: EXPERIMENTAL
Intervention: Office-based nasolacrimal duct probing
Number of subjects: 304
Study 23770182 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg bid
Number of subjects: 18113
Study 23770182 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg bid
Number of subjects: 18113
Study 20074388 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat vegan diet with weekly group meetings
Number of subjects: 109
Study 20074388 — intervention group
Group type: COMPARATOR
Intervention: Control group (no instruction)
Number of subjects: 109
Study 18952147 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal DC brain polarization of right parietal cortex, intensity 2.0 mA for 20 min
Number of subjects: 0
Study 18952147 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 0
Study 17038247 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition (EN) or EN supplemented with parenteral nutrition (EN+PN)
Number of subjects: 65
Study 17038247 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment only (Control)
Number of subjects: 65
Study 12505962 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine
Number of subjects: 50
Study 12505962 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 50
Study 10883352 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium
Number of subjects: 30
Study 10883352 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium
Number of subjects: 30
Study 8878242 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (n = 341) once daily for 5 days
Number of subjects: 677
Study 8878242 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (n = 336) three times daily for 10 days
Number of subjects: 677
Study 8315799 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural buprenorphine (Bn) 0.1-0.2 mg (group B, n = 41)
Number of subjects: 82
Study 8315799 — intervention group
Group type: COMPARATOR
Intervention: Epidural buprenorphine (Bn) 0.1-0.2 mg + 1% lidocaine (group BL, n = 41)
Number of subjects: 82
Study 8315799 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural buprenorphine (Bn) 0.1-0.2 mg (group B)
Number of subjects: 82
Study 8315799 — intervention group
Group type: COMPARATOR
Intervention: Epidural buprenorphine (Bn) 0.1-0.2 mg + 1% lidocaine (group BL)
Number of subjects: 82
Study 3788741 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 400 mg oral doses for a single day
Number of subjects: 30
Study 3788741 — intervention group
Group type: EXPERIMENTAL
Intervention: Three 200 mg oral doses for three days
Number of subjects: 30
Study 29922099 — intervention group
Group type: EXPERIMENTAL
Intervention: Annular closure device (ACD)
Number of subjects: 164
Study 29922099 — intervention group
Group type: COMPARATOR
Intervention: Non-Trial group (no ACD)
Number of subjects: 164
Study 29922099 — intervention group
Group type: COMPARATOR
Intervention: Non-Trial group
Number of subjects: 164
Study 29922099 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial group
Number of subjects: 164
Study 29922099 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 164
Study 27612167 — intervention group
Group type: EXPERIMENTAL
Intervention: Storytelling as part of a residential cancer rehabilitation intervention
Number of subjects: 20
Study 25551944 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral internal sphincterotomy
Number of subjects: 41
Study 25551944 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 41
Study 25551944 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient group (chronic anal fissure)
Number of subjects: 41
Study 25551944 — intervention group
Group type: COMPARATOR
Intervention: Comparison between patient group and control group
Number of subjects: 41
Study 24184336 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone Marrow (BM) donation
Number of subjects: 332
Study 24184336 — intervention group
Group type: COMPARATOR
Intervention: Peripheral Blood Stem Cell (PBSC) donation
Number of subjects: 332
Study 22488405 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-RAAP intervention
Number of subjects: 0
Study 20664906 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg/day for days 1-10; 300 mg on day 11)
Number of subjects: 0
Study 20664906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17971588 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial radiation therapy (CRT) with double intrathecal (IT) chemotherapy (methotrexate and cytarabine)
Number of subjects: 164
Study 17971588 — intervention group
Group type: COMPARATOR
Intervention: Intensive triple IT chemotherapy (methotrexate, cytarabine and hydrocortisone) without CRT
Number of subjects: 164
Study 15820996 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolve to Stop the Violence Project (RSVP)
Number of subjects: 56
Study 15820996 — intervention group
Group type: COMPARATOR
Intervention: Control dorm (traditional jail practices)
Number of subjects: 56
Study 12170410 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-l PEG-EL solution
Number of subjects: 200
Study 12170410 — intervention group
Group type: COMPARATOR
Intervention: Sodium phosphate (NaP)
Number of subjects: 200
Study 10558394 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use intervention
Number of subjects: 0
Study 10558394 — intervention group
Group type: COMPARATOR
Intervention: Ordinary least squares (OLS)
Number of subjects: 0
Study 10558394 — intervention group
Group type: COMPARATOR
Intervention: Multilevel estimators
Number of subjects: 0
Study 10163426 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone for 14 days
Number of subjects: 458
Study 10163426 — intervention group
Group type: COMPARATOR
Intervention: Zopiclone for at least 12 months
Number of subjects: 458
Study 10163426 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone
Number of subjects: 458
Study 1829439 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux polysulfone (PS) membrane with high heparin regimen (HHR) - 90 IU/kg body weight
Number of subjects: 8
Study 1829439 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux polyacrylonitrile (AN 69) membrane with high heparin regimen (HHR) - 90 IU/kg body weight
Number of subjects: 8
Study 1829439 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux polysulfone (PS) membrane with low heparin regimen (LHR) - 50 IU/kg body weight
Number of subjects: 8
Study 1829439 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux polyacrylonitrile (AN 69) membrane with low heparin regimen (LHR) - 50 IU/kg body weight
Number of subjects: 8
Study 1829439 — intervention group
Group type: EXPERIMENTAL
Intervention: Low heparin regimen (LHR)
Number of subjects: 8
Study 6360178 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoplasmapheresis
Number of subjects: 20
Study 6360178 — intervention group
Group type: COMPARATOR
Intervention: Control procedure (sham apheresis)
Number of subjects: 20
Study 30127374 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed consumption (30 g/day) for 12 weeks
Number of subjects: 50
Study 30127374 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 50
Study 29607568 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric education for nursing home staff
Number of subjects: 629
Study 29607568 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 629
Study 29607568 — intervention group
Group type: EXPERIMENTAL
Intervention: Special care unit in nursing home
Number of subjects: 629
Study 29607568 — intervention group
Group type: EXPERIMENTAL
Intervention: Fall in the last 12 months
Number of subjects: 629
Study 29607568 — intervention group
Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index
Number of subjects: 629
Study 29607568 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric advice and/or hospitalization in a psychiatric unit
Number of subjects: 629
Study 26837536 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional Card
Number of subjects: 80
Study 26837536 — intervention group
Group type: COMPARATOR
Intervention: Control (Standard post-operative instruction)
Number of subjects: 80
Study 24633366 — intervention group
Group type: EXPERIMENTAL
Intervention: EV71 vaccine (batch 1)
Number of subjects: 7263